Bengaluru: ACL Digital, a global leader in digital product innovation and engineering services, has announced the acquisition of Symbiance, a U.S.-based Contract Research Organization (CRO) with over 30 years of expertise in clinical data services, medical monitoring, biostatistics, statistical programming, medical writing, and pharmacovigilance.
The acquisition of Symbiance marks a significant milestone in the company’s expansion strategy, enabling the company to scale its clinical research capabilities and strengthen its presence in the life sciences sector.
With this move, ACL Digital reinforces its role as an end-to-end provider of CRO solutions, integrating AI-driven clinical research, pharmacovigilance, and data standardization into its offerings.
Also Read: Akums Partners with Government of Zambia to Establish Pharmaceutical Manufacturing Facility
Strategic Expansion for ACL Digital
Ramandeep Singh, CEO of ACL Digital, said, “We are pleased to welcome Symbiance. The acquisition aligns with our growth strategy, enhancing our capabilities and delivering patient-centric, transformative solutions that exceed the standards of the life sciences industry. Together, we are positioned to accelerate innovation and drive operational efficiency for our clients.”
Singh added that the combination of the company’s AI-powered solutions with Symbiance’s deep clinical research expertise will address the industry’s AI transformation needs and empower organizations with intelligent, data-driven insights for better outcomes.
Enhancing Global Life Sciences Portfolio
Sreejith Narayanan, Senior Vice President of Sales and Operations at ACL Digital, highlighted Symbiance’s strong reputation in the U.S. market. He noted that the acquisition further underscores the company’s commitment to becoming a global leader in digital solutions for clinical research, helping life sciences customers remain future-ready.
Also Read: AI in Biopharma: ThinkBio Ai and UST Launch Strategic Alliance
Ilango Ramanujam, President & CEO of Symbiance, expressed enthusiasm about the partnership: “We are elated to become an integral part of ACL Digital. Symbiance’s unique ‘people + product’ delivery model, combined with AI-powered analytics, will enhance ACL Digital’s clinical research service offerings and boost overall delivery capabilities for global clients.”
The acquisition of Symbiance positions ACL Digital to scale innovation, expand global clinical research operations, and strengthen its life sciences portfolio across pharmaceutical, biotech, and medical device industries.
